Manufacturing Strategy

The United States confronts a global competitive landscape that has radically transformed in the past decade. Fueled by global deployment of advanced telecommunications, trade liberalization, and economic reforms in many countries, globalization and integration of the world’s national economies have accelerated, and emerging economies represent a growing share of global business commerce. While these changes spread increased growth and economic opportunity around the world, the competitive arena is more crowed than ever before.

In the early years of the 21st Century, as a result of many changes, it has become possible for the first time for tens of thousands of companies to offer manufactured products to customers across six continents. For many of these "global products", there are potentially more than a billion customers. In 2007, Wall Street hit new highs as the enormous opportunity for increased sales and profits became clear. However the new environment is not easy to manage and the risks are high.

Beyond Six Sigma and Lean! Design your processes to facilitate real business growth, in both healthy and unhealthy economies

The formulation and the technological advancements in RNA biology, chemistry, stability, and encapsulated delivery systems that have enabled the development of fully synthetic mRNA vaccines are discussed in this volume. The applications of the mRNA technology is covered, focusing on infectious diseases but also touching on other indications, such as immunotherapies and molecular therapies. Potent and long-lasting immune responses observed in animal models, encouraging data from early human clinical studies, together with the success of two mRNA-based COVID-19 vaccines support the use of mRNA-based vaccination as an attractive alternative to conventional vaccine approaches.